A Phase II Study of Rivoceranib for Patients With Recurrent or Metastatic Olfactory Neuroblastoma

NCT06308575 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped PI Request--No Patient Accrual

Conditions

Metastatic Olfactory Neuroblastoma
Recurrent Olfactory Neuroblastoma

Interventions

DRUG: Rivoceranib

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]